Researchers estimated whether a hepatitis C vaccine could reduce transmission of the virus among injection drug users, even without providing complete immunity.
Hepatitis/MASH
Latest News
Advertisement
CME Content
Advertisement
Taking advantage of cost-effective generic medications can improve access to hepatitis B treatment, especially in countries with a high disease burden.
Top news of the day from across the health care landscape.
A new study provides insight into previously unknown details about the capsid that may have implications for the development of new drugs to treat the infection.
A new, inexpensive diagnostic test can help identify patients who require immediate treatment for hepatitis B virus across Africa.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape
Patients with both private and public insurers face high denial rates across the United States for life-saving hepatitis C drugs, despite changes in restrictions and increased price competition.
The hepatitis C virus (HCV) guidelines for unique populations have recently been updated.
Access to diagnosis and treatment must be improved worldwide to meet target goals for the elimination of viral hepatitis.
US report indicates new drivers of death have emerged over time and have continued to unequally affect residents at the state level.
Black patients may be eligible for a shorter course of hepatitis C virus treatment.
A recently-discovered hepatitis C virus subtype may complicate treatment.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
An artificial liver infected with hepatitis B demonstrates physiological reaction of a real human liver.
Health and Human Services Secretary Alex Azar could take action to help millions of Americans gain access to necessary drugs.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
More than 3 million Americans have chronic hepatitis C virus, and physicians diagnose about 17,000 new cases annually.
An experimental antiviral drug shows promise fighting multiple infectious diseases.
Patients who achieved hepatitis C virus eradication experienced a reduction in hepatic steatosis and fibrosis.
Researchers from the CDC assessed adverse effects (AEs) following HepB vaccinations using the Vaccine Adverse Event Reporting System (VAERS).
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
2
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
3
Emavusertib-Based Therapy Produces Responses in BTK Inhibitor–Treated Primary CNS Lymphoma
4
Online GLP-1 Sellers Often Skip Clinician Oversight, Secret Shopper Study Finds
5